Metastases From Nested Variant Urothelial Carcinoma of the Urinary Bladder in Pancreatic Allograft Mimicking Graft Rejection by Wang, Jue et al.
Case Report J Clin Med Res  •  2012;4(2):145-148
ress Elmer 
Articles © The authors   |   Journal compilation © J Clin Med Res and Elmer Press™   |   www.jocmr.org
Metastases From Nested Variant Urothelial Carcinoma of the 
Urinary Bladder in Pancreatic Allograft Mimicking 
Graft Rejection
Jue Wanga, e, Geoffrey Talmonb, Syed A. Jaffar Kazmib, 
Larry E. Sirefc, Michael C. Morrisd
Abstract
While not an uncommon tumor, urothelial carcinoma of the urinary 
bladder is rare in bladders draining pancreatic allografts. A case of 
urothelial carcinoma directly involving a pancreatic allograft with 
metastasis that occurred in a 49-year-old pancreas and kidney trans-
plant recipient is described. Her initial clinical presentation and 
findings of CT scan of the abdomen suggested pancreatitis with fea-
tures worrisome for rejection. A biopsy of her pancreatic allograft 
contained poorly differentiated carcinoma and cystoscopic biopsy 
disclosed an invasive high grade urothelial carcinoma arising in the 
background of extensive urothelial carcinoma in situ. Exploratory 
laparotomy revealed that the tumor invaded the right ovary and 
fallopian tube, cecum, and allograft with extensive retroperitoneal 
involvement. She underwent en bloc resection of distal ileum and 
cecum, resection of transplant pancreas, partial cystectomy, ileo-
colostomy anastomosis, and right salpingo-oophorectomy. Postop-
eratively, the patient was treated with four cycles of carboplatin 
and gemcitabine. She ultimately succumbed to her disease approxi-
mately 1 year after diagnosis. This case should alert physicians and 
radiologists to be aware of atypical presentation of urothelial carci-
noma in bladder-drained pancreas grafts, the aggressiveness of such 
lesions, and the need for early biopsy to avoid diagnostic confusion 
with rejection.
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Introduction
Bladder malignancy in the pancreas and kidney transplant 
recipient is rare with only a limited number of reported cases 
[1, 2]. Although the incidence of bladder cancer in organ re-
cipients appears to parallel that of the general population, the 
tumors are more likely to be high grade with an aggressive 
clinical course and poor response to chemotherapy. Among 
transplanted patients, the age of onset is younger (average 
44 years) without the typical male predominance [3-5]. The 
duration of immunosuppression associated with the develop-
ment of the urothelial malignancy varies from 2 years to >10 
years [3]. 
Here, this report illustrates an unusual presentation of 
urothelial carcinoma of the urinary bladder in a 49-year-
old kidney/pancreas transplant recipient which was initially 
thought clinically and radiologically to represent pancreatic 
graft rejection.
Case Report
A 49 year-old Caucasian woman was transferred to our hos-
pital with right flank and lower quadrant abdominal pain in 
March 2010. Her history was significant for type I diabetes 
mellitus,  hypertension,  hyperlipidemia,  end-stage  kidney 
disease. She was status-post two pancreatic transplants in 
1991 and 2006, as well as and four renal transplants (last in 
February 2000).  Seven months prior to this admission, she 
was diagnosed with a low grade noninvasive papillary uro-
thelial carcinoma. A repeat cystoscopy two months before 
this admission was negative for any gross evidence of tumor 
recurrence.  
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On admission, a computed tomography (CT) scan of the 
abdomen revealed peripancreatic fluid collections with in-
volvement of the cecal pole and urinary bladder. Findings 
were suggestive of pancreatitis and worrisome for rejection 
(Fig. 1). A biopsy of her pancreatic allograft revealed diffuse 
involvement by poorly differentiated carcinoma. A cystos-
copy with biopsy revealed an invasive high grade urothelial 
carcinoma arising in the background of extensive urothelial 
carcinoma in situ. A positron emission tomography (PET 
scan) showed an abnormally increased signal in the region of 
Figure 1. CT scan of abdomen reveals peripancreatic fluid collections with involvement of the cecal pole, 
findings suggestive for pancreatitis around the transplant. The pancreas transplant in the right lower quad-
rant is surrounded by inflammation and two fluid density areas. The inflammatory changes extend into the 
cecal pole area and involve this bowel loop. The inflammatory changes also extend towards the bowel, close 
to the urinary bladder. There is no fatty plane between the urinary bladder and the pancreas transplant with 
inflammation. The findings were initially concerning for pancreatitis with graft rejection.
Figure 2. Photomicrograph of specimen from (A) cystectomy specimen. Short arrow points to adjacent normal urothelium, long arrow 
to nests of tumor cells invading muscularis propria. (B) Ovary. Ovary involved by carcinoma via direct extension. Long arrows: tumor 
in ovarian stroma. Short arrow: corpus albicans. (C) The transplant pancreas. The long arrow points to nests of invasive carcinoma 
and the short arrow highlights the pancreatic parenchyma. The high-grade urothelial carcinoma shows a predominant invasive 
nested variant of urothelial carcinoma (NVUC) pattern.
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the pancreas, and anterior abdominal wall. Exploratory lapa-
rotomy revealed extensive tumor invading the right ovary 
and tube, the cecum, and the transplant pancreas with exten-
sive retroperitoneal involvement. Subsequently, she under-
went en bloc resection of distal ileum and cecum, resection 
of transplanted pancreas, partial cystectomy, right salpingo-
oophorectomy, and repair of ileocolostomy anastomosis. 
Pathologic examination of the resection specimen dis-
closed a 4.9 cm mass within bladder cuff near the allograft 
that directly invaded the right ovary, fallopian tube, cecum, 
and pancreas allograft (Fig. 2), as well as extensive retro-
peritoneal involvement. The tumor demonstrated a promi-
nent nested growth pattern reminiscent of the nested variant 
of urothelial carcinoma (NVUC) with other areas showing 
features more typical of conventional invasive high grade 
urothelial carcinoma. The neoplastic cells were positive for 
pancytokeratin and OC125 (cytoplasmic) while negative for 
chromogranin, synaptophysin, CD56, CK7, CK20, CDX2, 
TTF1, ER, PR, p53, and BRST2. While not entirely specific, 
the staining pattern combined with the presence of adjacent 
urothelial carcinoma in situ was supportive of an urothelial 
origin. In addition, the lesions resected from her abdominal 
wall were positive for metastatic urothelial carcinoma.
Postoperatively, the patient was given with four cycles 
of gemcitabine and carboplatin, which completed in August 
2010, with no measurable disease noted radiographically fol-
lowing therapy. In Feb 2011, the patient was admitted to jos-
pital for worsening of abdominal pain. A CT scan revealed 
multiple intra-abdominal and peritoneal nodules consistent 




Bladder cancer developing in organ transplant recipients re-
mains a challenging disease to manage as it has been demon-
strated that the clinical course seems worse than in the gen-
eral population [1-4]. The immunosuppressed status of the 
transplant recipients renders the therapy and post-treatment 
surveillance very difficult [5]. With the increase of organ 
transplantation, urological cancer (including bladder cancer) 
may pose a critical problem affecting the survival of these 
patients. 
NVUC was recently classified by the World Health Or-
ganization as an “uncommon aggressive tumor”, with few 
reported cases and a 70% mortality rate 4 to 40 months af-
ter diagnosis despite therapy [6]. The incidence of NVUC 
has been estimated to be 0.8% of all invasive bladder carci-
noma [7] and fewer than 100 cases have been reported [8-
11]. This variant exhibits aggressive clinical behavior with 
rapid spread along the lymphatics in the lamina propria of 
the urinary bladder and along lymphatic channels into the 
peritoneum [8]. 
While the degree of cytologic atypia noted in this case 
is not typically described in NVUC, this feature can be seen 
in these lesions and NVUC is associated with areas of con-
ventional high grade urothelial carcinoma in the majority of 
instances [12]. In the present case, her pancreas is bladder 
drained and it is possible that the atypia noted may be related 
to the effect of exocrine pancreatic secretions.  Indeed, clini-
cal behavior and pattern of spread is compatible with NVUC 
and cases with nested features have a poor outcome [12].
To our knowledge, this is the first case of urothelial car-
cinoma demonstrating NVUC features reported in the trans-
plant receipt, the tumor invaded the transplanted pancreas 
with extensive retroperitoneal involvement. This is a unique 
presentation that clinically mimicked pancreatitis and/or re-
jection. The rapid progression from a clinically nonapparent 
lesion widely invasive disease may be related to the patient’s 
immunosuppressive status, although as noted above lesions 
with nested growth patterns often demonstrate an aggressive 
phenotype. 
The  optimal  modality  of  treatment  is  uncertain  be-
cause NVUC is rare and no randomized studies specifically 
designed for this subtype of bladder tumor [7, 10]. Tradi-
tionally, the standard therapy for patients with locally ad-
vanced or metastatic urothelial carcinoma is chemotherapy 
using methotrexate, vinblastine, doxorubicin, and cisplatin 
(MVAC) [13]. The gemcitabine-cisplatin regimen has been 
shown to have equivalent overall response rates, with less 
toxicity (range 41% to 57%), with a complete response in 
15% to 22%, and a median survival of 12.5 to 14.3 months 
[14].  Although  this  subtype  of  urothelial  carcinoma  is 
thought to be resistant to radiotherapy and chemotherapy [7, 
8, 10], clinical experience with our case suggests that multi-
modality therapy including platinum based chemotherapy is 
beneficial. Multi-institution studies are needed to establish a 
better therapeutic protocol for these rare cases. 
In conclusion, this case report illustrates atypical presen-
tation of bladder cancer in a pancreas and kidney transplant 
recipient. Our experience should alert physicians and radi-
ologists of the possibility of malignancy in the differential 
diagnosis and the need for early biopsy to avoid diagnostic 
confusion with graft rejection.
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